Arthritis following recombinant outer surface protein A vaccination for Lyme disease.
As more individuals receive outer surface protein A (OspA) vaccination, adverse effects not detected during phase III clinical trials may become apparent. Although arthritis has been described following other human vaccines, we found no reports of human cases after Lyme disease vaccination. We describe 4 males (2 children, 2 adults) who developed arthritis following recombinant OspA vaccination. The potential arthritogenic effect of OspA suggested by in vitro and animal studies finds a clinical correlate in these 4 cases.
Rosé
C D
CD
Department of Pediatrics, duPont Hospital for Children, Wilmington, Delaware 19899, USA.
Fawcett
P T
PT
Gibney
K M
KM
D000293:Adolescent; D000328:Adult; D000954:Antigens, Surface / Q000009:adverse effects* / Q000276:immunology; D016918:Arthritis, Reactive / Q000209:etiology* / Q000276:immunology; D001425:Bacterial Outer Membrane Proteins / Q000009:adverse effects* / Q000276:immunology; D001428:Bacterial Vaccines; D002648:Child; D006801:Humans; D008074:Lipoproteins; D008193:Lyme Disease / Q000276:immunology / Q000517:prevention & control*; D022123:Lyme Disease Vaccines / Q000009:adverse effects* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D008074:Lipoproteins; D022123:Lyme Disease Vaccines; C072045:OspA protein; D011994:Recombinant Proteins